Theriva Biologics
Filed with the SEC on · accession 0001104659-26-125918
TOVX filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -1.2% by the first close after the filing.
Theriva Biologics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results and disclosures including an at-the-market offering program and various equity transactions.
Close before
$0.16
Nov 11, 2026
First close after
-1.18%
$0.16
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for TOVX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for TOVX?
Click hereTOVX filed a 10-Q (SEC filing). Theriva Biologics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results and disclosures including an at-the-market offering program and various equity transactions.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
TOVX closed at $0.16 before the filing and $0.16 on Nov 12, 2026 (-1.18%).
Get alerts when TOVX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days